Company Description
Agendia is a mission-driven, commercial stage company focused on enabling optimized decision-making by providing physicians with next-generation diagnostic and information solutions that can be used to help improve outcomes for breast cancer patients worldwide.
Our solutions apply the power of functional genomic profiling to help physicians guide the care of women throughout their patient journey, from initial diagnosis to remission and cure, or recurrence and metastatic disease.
Our scientific approach takes a holistic view of the biology underlying an individual patient’s breast cancer.
We currently offer two proprietary tests: MammaPrint and BluePrint. These two tests form a combined platform that is designed to enable accurate classification of personalized breast cancer types.
In pre- and post-operative settings, our platform provides clinically actionable insights that help guide optimal treatment decisions along the continuum of care.
We continue to advance our solutions with innovative analytical modalities such as whole genome arrays, next generation sequencing, or NGS, and digital AI pathology.
| Country | United States |
| Founded | 2003 |
| Industry | Health Care Providers & Services |
| Sector | Healthcare |
| Employees | 248 |
| CEO | Mark R. Straley |
Contact Details
Address: 22 Morgan Irvine, CA 92618 United States | |
| Phone | (888) 321-2732 |
| Website | agendia.com |
Stock Details
| Ticker Symbol | AGDX |
| Exchange | NASDAQ |
| Reporting Currency | USD |
| CIK Code | 0001601563 |
| SIC Code | 8071 |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 9, 2022 | RW | Filing |
| Oct 28, 2021 | F-1 | Registration statement for certain foreign private issuers |
| Oct 6, 2021 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Aug 23, 2021 | DRS | [Cover] Draft Registration Statement |